Our Tests
Our Tests

GENinCode test products have been developed to help physicians make improved clinical decisions.
By delivering comprehensive risk assessment we are able to stratify patients and identify the most appropriate treatment pathways aligned with clinical guidelines to ensure optimal outcome.

UK/EU Tests

CARDIO inCode-Score EU

CARDIO inCode-Score UK

LIPID inCode

SUDD inCode

THROMBO inCode

ROCA test

THROMBO inCode Reproductive Health

US Tests

US Homepage

Testing Resources

CARDIO inCode-Score

LIPID inCode

SITAB

About the SITAB Portal
Investors
Investors

Stay up to date on our shareholder news, view our financial performance and shareholder services.

Investor Overview

Financial Reports

Share Price & RNS

Corporate News

Directors

Corporate Video

AIM Rule 26

Investor Alert
News
SITAB Portal

Corporate News

2026

07 May

Grant of Share Options, Surrender of Existing Options & PDMR Dealings

15 April

Holding(s) in Company

14 April

Holding(s) in Company

26 February

Holding(s) in Company

24 February

Holding(s) in Company

12 February

Holding(s) in Company

12 February

Holding(s) in Company

12 February

Holding(s) in Company

09 February

Result of General Meeting, Director Shareholdings and Total Voting Rights

06 February

Additional Subscription

26 January

Result of Retail Offer

22 January

Result of Placing and Subscription

21 January

WRAP Retail Offer for up to £500,000

21 January

Placing and Subscription to raise a minimum of £3.5 million

2025

17 December

Collaboration with Sohin Genetics

08 December

Holding(s) in Company

04 December

CARDIO inCode-Score® collaboration with Thermo Fisher Scientific

03 December

New York State clinical test approval of CARDIO inCode-score®

27 October

Publication of Landmark Study in JACC: Advances

13 October

Holding(s) in Company

30 September

Interim results statement

25 September

NHS (UCLH) launches Risk of Ovarian Cancer (ROCA) surveillance service for women at high risk

24 September

Holding(s) in Company

17 September

Comment re: Share Price Movement

05 September

Notice of results

26 August

Trading update - H1 2025

07 July

De Novo Update - FDA Supervisory Review

30 June

04 June

16 May

Notice of results

30 April

De Novo Submission Update

26 March

Grant of Share Options & PDMR Dealings

06 March

Holding(s) in Company

05 March

Holding(s) in Company

04 March

Holding(s) in Company

03 March

Result of General Meeting, Issue of Equity and TVR

18 February

Result of Retail Offer

14 February

Result of Placing and Subscription

14 February

14 February

Placing and Subscription

23 January

CARDIO inCode® inclusion in the US CMS 2025 Clinical Lab Fee Schedule and launch in the Spanish region of Catalonia

2024

10 December

GENinCode partners with Genesupport SA for the ROCA® Test in Switzerland

05 December

CARDIO inCode® publication in International Journal of Cardiology Cardiovascular Risk and Prevention and 2024 Pre-Close Trading Update

25 September

20 September

DISCOVER FH collaboration with Family Heart Foundation®, UT Southwestern, and Partners

09 September

Notice of results

28 August

CARDIO inCode-Score® presentation on polygenic risk of Coronary Heart Disease at 2024 European Society of Cardiology (ESC) Annual Congress, London

27 June

05 June

Posting of Annual Report and Notice of Annual General Meeting

03 June

23 May

Notice of results

01 May

CARDIO inCode-Score® presentation at European Society of Cardiology Preventive Cardiology Congress

26 April

Grant of Options & Surrender of Existing Options

04 April

CARDIO inCode-Score® US study publication

21 March

New NICE Guidance for Ovarian Cancer

09 February

Holding(s) in Company

15 January

Holding(s) in Company

11 January

Holding(s) in Company

11 January

Holding(s) in Company

09 January

Result of GM and Total Voting Rights

2023

28 December

Result of Retail Offer

21 December

Result of Placing and Subscription

21 December

Retail Offer to raise up to £1.00 million via Bookbuild Platform

21 December

Placing and Subscription

29 November

GENinCode to transition CARDIO inCode-Score (CIC-SCORE) 510(k) FDA submission to De Novo pathway

29 November

Change of Adviser

12 October

ShareSoc investor presentation

20 September

13 September

Notice of results

30 August

CARDIO inCode® study

16 August

Premarket Notification 510(k) medical device filing for CARDIO inCode-Score (CIC-SCORE)

19 July

Collaboration with US healthcare provider

30 June

08 June

Posting of Annual Report to Shareholders and Notice of Annual General Meeting

06 June

05 June

Notice of results

22 May

CARDIO inCode® study for risk of incident Coronary Heart Disease to be presented at European Society of Cardiology Annual Meeting in Amsterdam

15 May

Collaboration with University Clinic Dresden for implementation of LIPID inCode®

02 May

NHS accelerates implementation of LIPID inCode® testing of patients suffering with hypercholesterolemia and familial hypercholesterolemia

03 April

US CPT PLA Code Granted for CARDIO inCode-SCORE (CIC-SCORE)

13 March

Statement re: Silicon Valley Bank

03 January

Approval of California state license and CLIA certification opens US market

2022

22 November

Issue of Share Options

03 November

British Medical Journal publication

10 October

Holding(s) in Company

27 September

Interim results for six months ended 30 June 2022

07 September

Notice of results

26 July

NHS implementation of Lipid inCode®

23 June

Result of Annual General Meeting

23 May

Posting of Annual Report to Shareholders and Notice of Annual General Meeting

17 May

03 May

Notice of results

06 April

Director appointment

23 March

Collaboration with Indiana University School of Medicine

15 March

NHS pilot for polygenic testing of UK patients suffering with hypercholesterolemia and familial hypercholesterolemia

21 February

Confirmation of board appointment

08 February

Positive results for Lipid inCode® in NHS clinical study

21 January

Proposed independent directorate appointment

10 January

FDA Pre-Submission filed for Cardio inCode-SCORE

2021

29 November

Directorate change

25 November

Trading and progress update

17 September

Grant of Share Options and PDMR dealing

16 September

Interim Results to 30 June 2021

10 September

Holding(s) in Company

02 September

Notice of Results

27 July

Holding(s) in Company

26 July

Positive Thrombo inCode clinical results

23 July

Holding(s) in Company

23 July

Holding(s) in Company

22 July

Admission to trading on AIM & First Day of Dealings

19 July

Investor presentation